BRCA1 and ovarian carcinoma: Although not statistically significant, the molecular response was more frequently observed in patients with clinical benefit versus not (66% vs. 25% and 69% vs. 40% in ovarian cancer and BRCA1/2 mutant subgroups, respectively) (74).